Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles

Executive Summary

Barr's claim to 180 days of generic exclusivity for fluoxetine will depend on the outcome of judicial and regulatory proceedings over the next year.

You may also be interested in...



Barr Fluoxetine Will Have Two Months Exclusivity Under "Worst Case"

Barr believes that in a worst case scenario it will still have two months of Waxman/Hatch exclusivity for its generic version of Prozac (fluoxetine).

Barr Fluoxetine Will Have Two Months Exclusivity Under "Worst Case"

Barr believes that in a worst case scenario it will still have two months of Waxman/Hatch exclusivity for its generic version of Prozac (fluoxetine).

Barr, FDA In Discussions On Trigger For Generic Prozac Exclusivity

Barr's 180 days of Waxman/Hatch exclusivity for generic fluoxetine could depend on FDA's determination of whether a brand name company's pediatric exclusivity supercedes generic exclusivity, Barr told analysts during its quarterly conference call Oct. 24.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel